KR102893040B1 - 독성이 감소된 혼성 암포테리신 b 유도체 - Google Patents

독성이 감소된 혼성 암포테리신 b 유도체

Info

Publication number
KR102893040B1
KR102893040B1 KR1020217010183A KR20217010183A KR102893040B1 KR 102893040 B1 KR102893040 B1 KR 102893040B1 KR 1020217010183 A KR1020217010183 A KR 1020217010183A KR 20217010183 A KR20217010183 A KR 20217010183A KR 102893040 B1 KR102893040 B1 KR 102893040B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
delete delete
cycloalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217010183A
Other languages
English (en)
Korean (ko)
Other versions
KR20210064247A (ko
Inventor
마틴 디. 버크
지아바오 장
아누즈 칸델왈 (사망)
안나 산타마리아
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20210064247A publication Critical patent/KR20210064247A/ko
Application granted granted Critical
Publication of KR102893040B1 publication Critical patent/KR102893040B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020217010183A 2018-09-07 2019-09-06 독성이 감소된 혼성 암포테리신 b 유도체 Active KR102893040B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728203P 2018-09-07 2018-09-07
US62/728,203 2018-09-07
PCT/US2019/049971 WO2020051465A1 (en) 2018-09-07 2019-09-06 Hybrid amphotericin b derivatives with reduced toxicity

Publications (2)

Publication Number Publication Date
KR20210064247A KR20210064247A (ko) 2021-06-02
KR102893040B1 true KR102893040B1 (ko) 2025-11-27

Family

ID=69719049

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010183A Active KR102893040B1 (ko) 2018-09-07 2019-09-06 독성이 감소된 혼성 암포테리신 b 유도체

Country Status (8)

Country Link
US (1) US11198705B2 (https=)
EP (1) EP3846823A4 (https=)
JP (1) JP7477177B2 (https=)
KR (1) KR102893040B1 (https=)
CN (1) CN113056274A (https=)
AU (1) AU2019335409B2 (https=)
CA (1) CA3111565A1 (https=)
WO (1) WO2020051465A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111565A1 (en) 2018-09-07 2020-03-12 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity
KR20220058547A (ko) * 2019-08-08 2022-05-09 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 감소된 독성을 갖는 하이브리드 암포테리신 b 유도체
AU2021325676A1 (en) * 2020-08-10 2023-03-30 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168568A1 (en) * 2015-04-15 2016-10-20 Revolution Medicines, Inc. Derivatives of amphotericin b

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102548341B1 (ko) * 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
ES2749927T3 (es) * 2014-05-16 2020-03-24 Univ Illinois Derivado de anfotericina b con toxicidad reducida
MA39568A1 (fr) * 2014-06-12 2017-09-29 Shionogi & Co Dérivé de macrolide de polyène
WO2017100171A1 (en) * 2015-12-08 2017-06-15 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods
CA3111565A1 (en) 2018-09-07 2020-03-12 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168568A1 (en) * 2015-04-15 2016-10-20 Revolution Medicines, Inc. Derivatives of amphotericin b

Also Published As

Publication number Publication date
WO2020051465A1 (en) 2020-03-12
AU2019335409B2 (en) 2025-06-05
JP7477177B2 (ja) 2024-05-01
CN113056274A (zh) 2021-06-29
CA3111565A1 (en) 2020-03-12
AU2019335409A1 (en) 2021-05-06
EP3846823A4 (en) 2022-04-20
US20200079811A1 (en) 2020-03-12
JP2021536462A (ja) 2021-12-27
US11198705B2 (en) 2021-12-14
EP3846823A1 (en) 2021-07-14
KR20210064247A (ko) 2021-06-02

Similar Documents

Publication Publication Date Title
AU2019279928B2 (en) Amphotericin B derivatives with improved therapeutic index
CN111225665A (zh) 大环免疫调节剂
JP7240811B2 (ja) アムホテリシンｂの誘導体
KR102893040B1 (ko) 독성이 감소된 혼성 암포테리신 b 유도체
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
JP6726192B2 (ja) アムホテリシンｂの尿素誘導体の簡便な合成法
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
WO2016040779A1 (en) Urea derivatives of polyene macrolide antibiotics
KR20220058547A (ko) 감소된 독성을 갖는 하이브리드 암포테리신 b 유도체
NZ719529B2 (en) Amphotericin b derivatives with improved therapeutic index
NZ757647B2 (en) Amphotericin B derivatives with improved therapeutic index

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)